Introduction
The steroid hormone 1a,25-dihydroxyvitamin D 3 (vitamin D 3 ) plays an important role in the regulation of numerous physiological and cellular processes including calcium and phosphorous homeostasis, cell growth, differentiation and apoptosis (Jones et al., 1998; Deluca and Cantorna, 2001; Gurlek et al., 2002) . The biological effect of vitamin D 3 is mainly mediated via the vitamin D 3 receptor (VDR). Binding of vitamin D 3 to VDR promotes the interaction between VDR and retinoid X receptor (RXR) and enhances the formation of VDR/ RXR heterodimer. The heterodimer then attaches to the vitamin D 3 response element (VDRE) in the promoter of target genes to trigger gene transcription (Shigeaki, 2000; Khorasanizadeh and Rastinejad, 2001) . In addition to classic genomic action, recent studies demonstrate that vitamin D 3 may activate several intracellular signaling pathways such as extracellular signal-regulated kinases (ERKs), c-Src kinase and phospholipases in a nongenomic fashion (Buitrago et al., 2000; Boyan et al., 2002; Christakos et al., 2003; Schwartz et al., 2003) .
Epidemiological studies indicate that vitamin D 3 deficiency is linked with increased risk of development of several types of cancer including breast, prostate and colon (Martinez et al., 1996; Narvaez et al., 2001; Johnson et al., 2002) . In vitro and in vivo studies show that vitamin D 3 may inhibit proliferation of cancer cells (Liu et al., 2002; Yang et al., 2002; Kumagai et al., 2003) . In addition, preclinical study demonstrates that vitamin D 3 and its synthetic analogs exhibit potent chemopreventive activity (Guyton et al., 2001) . However, the molecular mechanisms mediated the antiproliferative and chemopreventive effects of vitamin D 3 are not well defined. Two possible candidates participate in the inhibition of cell growth by vitamin D 3 are p21 and p27 Kip1 . These two proteins are cyclin-dependent kinase (CDK) inhibitors that may negatively regulate the cyclin/CDK activity to inhibit cell cycle progression (Harper, 1997; Hengst and Reed, 1998) . The mechanism by which vitamin D 3 activates p21 has been characterized. A functional VDRE was identified in the p21
Waf-1 promoter and was shown to be involved in the induction of p21
Waf-1 by vitamin D 3 (Liu et al., 1996) . Therefore, vitamin D 3 induces p21
Waf-1 expression via a classic genomic mechanism. Conversely, the mechanism by which vitamin D 3 activates p27
Kip1 is still unclear. A recent study showed that vitamin D 3 stimulated transcription of p27
Kip1 via Sp1 and NF-Y transcription factor binding sites localized within the À555/À512 region of the promoter (Inoue et al., 1999) . Since no canonical VDRE was identified in the p27
Kip1 promoter, the authors concluded that VDR was not required for the induction of p27
Kip1 by vitamin D 3 . However, no experimental data has been provided to support this conclusion.
Recent studies demonstrate that nuclear receptors, instead of direct binding to the response element, may interact with other transcription factors to activate gene transcription. For example, 17b-estradiol (E 2 ) induces the formation of estrogen receptor (ER)/Sp1 complex and activates gene expression via the GC-rich Sp1 site (Sun et al., 1998; Safe, 2001) . Similarly, progesterone receptor may stimulate p21
Waf-1 via an Sp1 consensus site by interacting with Sp1 (Gareth et al., 1998) (Shabahang et al., 1993 (Shabahang et al., , 1994 . Small interference RNA (siRNA) was used to inhibit Sp1 expression. As shown in Figure 2a , Sp1-specific siRNA, but not nonspecific double-strand RNA, significantly suppressed Sp1 protein level in LNCaP cells. We found that transfection with nonspecific double RNA did not change the effect of vitamin D 3 on the activation of p27 Kip1 and a 3.2-fold increase of promoter activity was found after vitamin D 3 stimulation (Figure 2b ). On the contrary, the induction was reduced to 1.5-fold in cells transfected with Sp1-specific siRNA. These results suggest that VDR and Sp1 may act synergistically in the activation of p27 Binding of VDR to oligonucleotides corresponding to the À555/À512 region of the human p27 kip1 promoter
To confirm that VDR may interact with Sp1 to activate the p27 Kip1 promoter activity, we investigated whether VDR bound to the response element localized within the À555/À512 region of the p27 Kip1 promoter. Because the conventional electrophoretic mobility shift assay is difficult to identify and quantify the proteins bound to a sequence-specific DNA probe, we used biotinated DNA probe to interact with nuclear extract proteins and precipitated the DNA-protein complex by streptavidincoated beads. As demonstrated in Figure 3a , our results Kip1 promoter activity. SW620 cells were co-transfected with p27
Kip1 promoter-luciferase vector and 1 mg of control (C) or VDR expression vector (VDR) for 24 h. Cells were then stimulated with vehicle (À) or 10 nM of vitamin D 3 ( þ ) for another 48 h and promoter activity was assayed. Results of three independent experiments were expressed as mean7s.d. *Po0.05 when the luciferase activity of vitamin D 3 -treated cells was compared to that of vehicle-treated cells showed that protein level of Sp1 and VDR in the nuclear extract of LNCaP cells was similar after treatment of vitamin D 3 for 24 h. A small reduction of nuclear NF-YA proteins was observed in vitamin D 3 -treated cells. As expected, we found that Sp1 and NF-YA bound to the DNA probe since the DNA probe containing the binding sites for these two transcription factors (Figure 3b ). The binding affinity of Sp1 and NF-YA to the DNA probe was not significantly changed after treatment of vitamin D 3 . Interestingly, our data showed that a small amount of VDR protein in the nuclear extract of unstimulated LNCaP cells bound to the DNA probe ( Figure 3b ). Treatment of vitamin D 3 significantly increased the binding of VDR to the DNA probe that contains only Sp1 and NF-Y consensus sequences. However, in vitro binding assay using purified VDR protein indicated that VDR could not bind directly to this DNA probe (data not shown). These results indicate that VDR may interact with Sp1 to bind to the p27 Kip1 promoter. To verify that VDR indeed bound to the À555/À512 region of human p27
Kip1 promoter in vivo, we performed chromatin immunoprecipitation (CHIP) assay with anti-VDR antibody to precipitate VDR. As shown in Figure 4 , VDR was found to be physically associated with the promoter region of p27 Kip1 in cell extracts precipitated by VDR-specific antibody, not in those precipitated by p57
Kip2 and the binding affinity of VDR to p27
Kip1 promoter was significantly increased after vitamin D 3 treatment. Therefore, VDR can bind to the p27 Kip1 promoter in vivo.
VDR interacts with Sp1 in vitro and in cells
We next investigated the interaction of VDR and Sp1 by protein binding assay. Our results indicated that VDR might interact with Sp1 in vitro (Figure 5a ). By using a number of GST fusion proteins containing various domains of Sp1, we also identified that both N-terminal (1-283 a.a.) and C-terminal (611-778 a.a.) of Sp1 was involved in its binding to VDR. Immunoprecipitation/ Figure 4 Association of VDR with p27 Kip1 promoter in vivo. LNCaP cells were treated without (À) or with ( þ ) vitamin D 3 for 6 h and cross-linked with 1% formaldehyde. Nuclear lysate was prepared and incubated with anti-VDR or p57
Kip2 antibody. The immunocomplex was precipitated with protein A/G agarose and DNA was then recovered and was subjected to PCR amplification by using the primers specific for the detection of the À690/À455 region that contained the Sp1 and NF-Y binding sites of human p27
Kip1 promoter. The sequences for the primers are: sense 5 0 -CAGGTTTGTTGGCAGCAGTA-3 0 , antisense 5 0 -GGAG GCTGACGAAGAAGAAA-3 0 and the predicted size for the PCR product is 235 bp Kip1 -specific DNA probe and 45 ml of 4% streptavidin-coated beads (Sigma) at room temperature for 1 h with shaking. Proteins bound to the beads were eluted and separated by SDS-PAGE. Immunoblotting was done as described above to investigate the proteins that bound to the DNA probe VDR and Sp1 in p27
Kip1 activation Y-C Huang et al Western blot analysis was performed to verify the results of in vitro binding assay. Our results showed that VDR and Sp1 could be co-immunoprecipitated from the lysate of LNCaP cells and vitamin D 3 increased the interaction of these two proteins (Figure 5b and c) .
Discussion
Steroid hormones exert their biological actions mainly via the nuclear receptor-mediated control of target genes. Upon ligand stimulation, nuclear receptors form homodimers or heterodimers and these dimers then bind to specific enhancer elements, referred to as nuclear receptor response elements for steroid hormone-induced gene transactivation (Olefsky, 2001) . However, recent studies demonstrate that steroid hormones may act via other transcription factors to activate target genes. For example, E 2 may stimulate a number of target genes including E2F, cathepsin D, c-fos and bcl-2 through one or more GC-rich Sp1 binding sites (Duan et al., 1998; Wang et al., 1998; Dong et al., 1999) . These studies establish a new model by which steroid hormones activate gene expression and provide a new concept that steroid hormone can stimulate the expression of genes in which no consensus hormone response elements are identified in their promoters. Whether VDR can act like ER to activate gene expression via interaction with other transcription factors is largely unknown. In this study, we provide clear evidences that VDR physically interacts with Sp1 to activate p27
Kip1 promoter via a GCrich Sp1 site. Interestingly, two recent studies also demonstrate that VDR interacts with STAT-1 and bcatenin to modulate gene expression (Palmer et al., 2001; Vidal et al., 2002) . These results strongly support the notion that VDR may activate gene expression via interaction with other transcription factors and the number of target genes that can be regulated by vitamin D 3 is larger than originally thought. For example, a previous study has demonstrated that vitamin D 3 might induce the expression of CD14, a differentiation marker for the monocyte/macro-phage lineage, in U937 cells (Zhang et al., 1994) . However, no VDRE is identified in the CD14 promoter and the effect of vitamin D 3 was found to be mediated via Sp1. Because vitamin D 3 plays an important role in the regulation of calcium and phosphorous homeostasis, cell growth, differentiation and apoptosis, it is possible that vitamin D 3 may control some of genes that involved in these physiological processes via the VDR/Sp1 complex and identification of these target genes will be helpful for the understanding of the biological action of vitamin D 3 . The molecular mechanism by which VDR enhances Sp1-mediated transactivation is currently unknown. Two possible models for the functional interaction between VDR and Sp1 can be suggested. First, VDR may increase the stability of Sp1-GC-rich DNA interaction and stimulate the expression of target genes via the Sp1 transactivation domain. Second, Sp1 may serve as an anchor protein for VDR. After binding, VDR may recruit the transcription apparatus by its own transactivation domain to activate gene expression. A recent study on the domains of ER required for ER/Sp1-mediated activation of GC-rich promoters by estrogen has indicated that multiple regions (including DNA binding domain, activation functions 1 and 2 are important for ER/Sp1 action (Kim et al., 2003) . Therefore, the functional interaction between nuclear receptors and transcription factors for gene activation is complex.
Additionally, the role of NF-Y in vitamin D 3 -induced gene expression is not clear. The binding sequence for NF-Y is present in the promoter region of many eukaryotic genes. However, not all of these genes can be activated by vitamin D 3 . It is possible that NF-Y must cooperate with other transcription factors to mediate the effect of vitamin D 3 on gene transcription. This is one of the reasons why vitamin D 3 activates gene expression in a gene-and cell-specific manner. Corporation of Sp1 and NF-Y in the activation of gene expression has been reported in a number of studies (Ge et al., 2002; Lok et al., 2002; Valor et al., 2002) . It is possible that NF-Y may form a NF-Y/Sp1/nuclear receptor complex to transactivate target genes. Indeed, a previous study demonstrated that transcriptional activation of E2F1 gene expression by E 2 in MCF-7 breast cancer cells is regulated by the NF-Y/Sp1/ER interactions. The authors found that Sp1 might coimmunoprecipitate with NF-YA . In addition, a very recent work also indicated that progesterone receptor might interact with Sp1/NF-Y complex to regulate gene transcription (Hewetson and Chilton, 2003) . These results strongly support the notion that NF-Y may form a multiprotein complex with Sp1/ nuclear receptor to modulate gene expression. Further works will be needed to elucidate the mechanism by which VDR activates expression of target genes via a unique transacting protein complex.
Materials and methods

Expression vectors, reporter plasmids and experimental reagents
Full-length GST-Sp1 plasmid was generous gifts of Dr H Rotheneder (Rotheneder et al., 1999) . CMV-VDR expression vector was obtained from Dr L P Freedman (Towers et al., 1993) . p27
Kip1 promoter-luciferase construct and its deletion mutants were generously provided by Dr T Sakai (Minami et al., 1997) . Sp1 and p27
Kip1 antibodies were purchased from Santa Cruz (Santa Cruz, CA, USA). Anti-VDR antibody was obtained from Biomol (Polymouth Meeting, PA, USA). LipofectAMINE reagent was obtained from Invitrogen (Carlsbad, CA, USA) and luciferase assay system was obtained from Promega (Madison, WI, USA). Vitamin D 3 was purchased from Calbiochem.
Cell culture SW620 colon cancer cells and LNCaP prostate cancer cells were cultured in DMEM/F12 and RPMI 1240 medium, respectively, containing 10% charcoal-treated fetal calf serum (FCS) and antibiotics.
Promoter activity assays
Promoter activity assays were performed as described previously (Huang et al., 2002) . In brief, cells were plated onto sixwell plates at the density of 100 000 cells/well and grown overnight. Cells were co-transfected with 2 mg of p27 Kip1 promoter-luciferase vector and 1 mg of CMV-VDR expression vector or control vector. After transfection, cells were cultured in 10% charcoal-treated FCS medium for 24 h followed by stimulation with vehicle (0.5% DMSO) or vitamin D 3 (10 nM) for another 48 h. Luciferase activity was determined by using a reporter assay system (Promega) and normalized for protein concentration in cell lysate. Data of three independent experiments were expressed as mean7s.d. Paired results were evaluated by Student's t-test and P-value o0.05 was considered significant.
Immunoprecipitation and immunoblotting
For immunoblotting, cells were harvested in a lysis buffer and equal amount of cellular proteins was subjected to SDSpolyacrylamide gel electrophoresis (SDS-PAGE) as described previously (Huang et al., 2002) . Proteins were transferred to nitrocellulose membranes and blots were probed with different primary antibodies followed by horseradish peroxidase-labeled secondary antibodies. Enhanced chemiluminescence reagent was used to depict the protein bands on the blots. For immunoprecipitation, cell lysate containing 200 mg of cellular proteins was incubated with anti-Sp1 or anti-VDR antibody at 41C for 2 h and the immunocomplex was collected by protein A/G agarose. Proteins were released by boiling in SDS-PAGE loading buffer and subjected to SDS-PAGE analysis. Immunoblotting was performed by probing the blots with antiSp1 or anti-VDR antibody to detect the interaction between Sp1 and VDR.
siRNA experiments siRNA designed to target Sp1 5 0 -GUAGCAGCACAGGCA-GUAGUU-3 0 (sense strand) and a nonspecific RNA 5 0 -AACGUUGCGAUAGCGUAGUAC-3 0 was synthesized (Dharmacon Research Inc., USA). LNCaP cells were transfected with p27
Kip1 promoter-luciferase construct and doublestrand RNA by using the LipofectAMINE reagent as described previously . After transfection, cells were incubated in 10% FCS medium for 48 h followed by stimulation with vehicle (0.5% DMSO) or vitamin D 3 (10 nM) for 24 h. Luciferase activity was determined by using a reporter assay system (Promega) and normalized for protein concentration in cell lysate. Results of three independent experiments were expressed as mean7s.d. Protein level of Sp1 in cells was examined by immunoblotting as described above.
DNA-protein binding assay
As the conventional electrophoretic mobility shift assay is difficult to identify and quantify the proteins bound to a sequence-specific DNA probe, we used a method developed by Zhu et al. (2002) by using streptavidin-coated beads to bind biotinated DNA probe, which was used to interact with nuclear extract proteins. After centrifugation, the pelleted beads were collected and washed, and proteins bound to the DNA probe were eluted by SDS-PAGE loading buffer and separated by 7.5% polyacrylamide gels. The separated proteins were analysed by immunoblotting. The sequence of DNA probe used in this study is: 5 0 -CGAGCCTCGGCGGGGCG GCTCCCGCCGCCGCAACCAATGGATCT-3 0 corresponding to the À555/À512 region of human p27
Kip1 promoter.
Nuclear extract was prepared as described previously (Pan and Hung, 2002) and 200 mg of nuclear extract proteins was incubated with 6 mg of biotinated p27
Kip1
-specific DNA probe and 45 ml of 4% streptavidin-coated beads (Calbiochem) at room temperature for 1 h with shaking. The bead concentration was in excess to lessen binding of nuclear extract proteins to free biotinated DNA probes. Beads were pelleted and washed with cold phosphate-buffered saline (PBS) for three times. Proteins bound to the DNA probe were eluted and separated by SDS-PAGE. Immunoblotting was done as described above to investigate the proteins that bound to the DNA probe.
CHIP assay
Vehicle (0.5% DMSO)-or vitamin D 3 (10 nM)-treated LNCaP cells were fixed with 1% formaldehyde at 371 for 10 min. Cells were washed twice with ice-cold PBS with protease inhibitors (1 mM phenylmethylsulphonyl fluoride, 1 mg/ml aprotinin and 1 mg/ml pepstatin A), scraped and pelleted by centrifugation at 41C. Cells were resuspended in lysis buffer (1% SDS, 10 mM EDTA and 50 mM Tris-HCl, pH 8.1), incubated for 10 min on ice, and sonicated to shear DNA. After sonication, lysate was centrifuged for 10 min at 13 000 r.p.m. at 41C. The supernatant was diluted in CHIP dilution buffer (0.01% SDS, 1% Triton X-100, 2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl and protease inhibitors). Anti-VDR or anti-p57
Kip2 antibody were added to the supernatant and incubated overnight at 41C with rotation. The immunocomplex was collected by protein A/G agarose and washed sequentially with low salt washing buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 200 mM Tris-HCl, pH 8.1 and 150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 200 mM Tris-HCl, pH 8.1 and 500 mM NaCl), LiCl washing buffer (0.25 M LiCl, 1% NP40, 1% deoxycolate, 1 mM EDTA and 10 mM Tris-HCl, pH 8.1) and finally 1 Â TE buffer (10 mM Tris-HCl and 1 mM EDTA, pH 8.0). The immunocomplex was eluted by elution buffer (1% SDS, 0.1 M NaHCO 3 and 200 mM NaCl) and the cross-links were reversed by heating at 651C for 4 h. After reaction, the samples were adjusted to 10 mM EDTA, 20 mM Tris-HCl, pH 6.5 and 40 mg/ml Proteinase K, and incubated at 451C for 1 h. DNA was then recovered and was subjected to PCR amplification by using the primers specific for the detection of the À690/À455 region that contained the Sp1 and NF-Y transcription factor binding sites of human p27 
Expression of GST-Sp1 and hisx6-VDR fusion protein
GST-Sp1 expression vector was transfected into BL21 cells and expressed proteins were purified by glutathione beads according to the procedures of manufacturer (Clontech). cDNA of VDR was excised from CMV-VDR expression vector and subcloned into the pET30a( þ ) vector. Hisx6-tagged VDR protein was expressed in BL21 cells and purified by nickel-resin column according to the procedures of manufacturer (Qiagen).
In vitro protein binding assay
Hisx6-tagged VDR protein was incubated with GST-Sp1 fusion protein in the protein binding buffer (20 mM HEPES, pH 7.5, 75 mM NaCl, 1 mM EDTA, 2 mM MgCl 2 , 2 mM DTT, 1% Triton X-100 and 200 mg/ml bovine serum albumin) for overnight at 41C with continuous rocking. Anti-VDR antibody and protein A/G agarose beads were added to pellet VDR protein and the beads were washed five times with protein binding buffer. The bound proteins were eluted by boiling in SDS-PAGE loading buffer and subjected to SDS-PAGE. Immunoblotting was performed by probing the blots with anti-GST antibody to detect the interaction between Sp1 and VDR.
